T

Tissium

www.tissium.com link_icon

Company Research Report: TISSIUM



Company Overview



  • Name: TISSIUM


  • Mission of the Company: The mission of TISSIUM is to disrupt the field of surgery and positively impact the lives of patients through the development of their platform of biomorphic programmable polymers.


  • Founding and Founders: TISSIUM was founded in 2013.


  • Founders: Jeff Karp, Robert Langer, Christophe Bancel, and Bernard Gilly.


  • Key People:

  • Christophe Bancel, Co-Founder, Chief Executive Officer

  • Maria Pereira, Co-Founder, Chief Innovation Officer

  • Hunt Henrie, Chief Business Officer

  • Thierry Darnis, Vice President Global Operations

  • Romain Attard, Chief Financial Officer

  • Ruth Krestin, Vice President Portfolio Strategy

  • Alex Milstein, Chief Medical Officer

  • Thierry Proust, Senior Director Human Resources


  • Headquarters: Paris, France, with operations also in Boston, USA.


  • Number of Employees: No information is available.


  • Revenue: No information is available.


  • Known For: TISSIUM is known for developing proprietary biomorphic programmable polymers aimed at tissue reconstruction.


Products



  • Product Offering:

  • TISSIUM offers solutions such as tissue sealants, tissue fixation products, and 3D-printed implants.


  • High-level Description and Features:

  • Biomorphic Programmable Polymers: Enable tissue reconstruction adaptable for multiple clinical areas. Their unique properties include conforming to and integrating with surrounding tissues, and programmability which allows for polymer building blocks to match tissue-specific requirements.

  • Tissue Sealants: Designed for cardiovascular procedures.

  • Tissue Fixation: Solutions for peripheral nerve and gastrointestinal procedures are developed.

  • 3D-Printed Implants: 3D printing technologies are used for designing surgical scaffolds for peripheral nerve repair.

  • Localized Drug Delivery: Formulations for drug-eluting solutions aid in tissue repair.


Recent Developments



  • Recent Developments:

  • First patients have been treated with TISSIUM's Atraumatic Hernia Repair System (September 12, 2023).

  • In March 2023, first patients were treated with TISSIUM’s Atraumatic Sutureless Nerve Coaptation System.

  • TISSIUM raised €50 million in Series D Funding to boost their commercial launch and platform extension.

  • Non-dilutive financing of €4.2 million obtained under the “FRANCE 2030” plan.


  • New Products Launched: Atraumatic Hernia Repair System and Atraumatic Sutureless Nerve Coaptation System.


  • New Features Added to Existing Products: No specific information is available.


  • New Partnerships and Recognitions:

  • TISSIUM was selected for the French Tech 120 Program multiple times, most recently in February 2023.

  • Collaborated with the Crohn’s & Colitis Foundation for gastrointestinal solutions.


Achievements



  • Achievements:

  • 3 CE Marks

  • 64 Patents Granted

  • 37 Patents Pending

  • 9 Publications


  • Notable Publications:

  • "Evaluation of a biocompatible sealant for on-demand repair of vascular defects—a chronic study in a large animal model"

  • "Preclinical and Clinical Evaluation of a Novel Synthetic Bioresorbable, On-demand, Light-activated Sealant in Vascular Reconstruction"

  • "A Blood-resistant Surgical Glue for Minimally Invasive Repair of Vessels and Heart Defects"


This structured report provides a deep dive into the company TISSIUM, focusing on its core products, notable developments, and key achievements within the company landscape.